Hematologic Oncology

Rami Komrokji, MD, and Gail Roboz, MD, discuss the importance of staging models in the diagnosis and routine assessment of patients with myelodysplastic syndrome.

Data presented during the 2021 ASCO Annual Meeting offered insight into the optimization of BTK inhibitors, induction therapy, consolidative therapy, and radiation therapy for patients across the paradigm of hematologic malignancies.

Key opinion leaders in acute myeloid leukemia reflect on challenges associated with molecular testing by commenting on potential treatment delay from the long turnaround time (TAT) of next-generation sequencing.

An expert of panelists provide an overview of TA-TMA, including findings that raise suspicion of this complication, strategies they use for making the diagnosis, and how they intervene given limited treatment options.

Mark Levis, MD, PhD, leads a panel of experts in a discussion on factors to consider when ordering molecular testing for newly diagnosed and relapsed/refractory acute myeloid leukemia.

David Sallman, MD, discusses the efficacy of pevonedistat plus azacitidine in higher-risk myelodysplastic syndrome.

Daniel Pollyea, MD, MS, discusses emerging therapies in higher-risk myelodysplastic syndrome.

The FDA has granted a breakthrough therapy designation to the combination of venetoclax plus azacitidine for use in the treatment of adult patients with previously untreated, intermediate-, high-, and very high–risk myelodysplastic syndromes based on the revised International Prognostic Scoring System.

The investigational therapy ficlatuzumab in combination with cytarabine demonstrated encouraging clinical efficacy with favorable tolerability when used as a treatment in patients with high-risk acute myeloid leukemia.

Tycel Jovelle Phillips, MD, of the University of Michigan, comments on his preferences for treating patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and shares his expectations for sequencing with newer, novel approaches emerging in the field.

Belumosudil induced clinically meaningful, durable responses in patients with chronic graft-versus-host-disease, irrespective of previous treatment received, severity of disease, and number of organs involved.

Recommendations for mitigating and managing common treatment-related adverse events associated with loncastuximab tesirine based on safety data from LOTIS-2 and variables that may impact patient candidacy.

Expert panelists review important disease-related and patient-related factors when considering bone marrow transplant in patients with primary myelofibrosis.

Dr. Jabbour discusses the optimal use of ponatinib in chronic myeloid leukemia and data from the 2021 ASCO Annual Meeting with the combination of blinatumomab and ponatinib in Ph-positive acute lymphoblastic leukemia.

Ruxolitinib continued to result in a significant improvement in overall response rate compared with best available therapy in patients with steroid-refractory/dependent chronic graft-vs-host disease, regardless of the individual organs involved at baseline.

David Rizzieri, MD, discusses new data from the ASCO 2021 Virtual Meeting regarding CNS lymphoma and treatment approaches in this setting.

A panel of experts explain how they approach CNS prophylaxis in DLBCL.

Ehab L. Atallah, MD, discusses the clinical implications of the phase 3 QUAZAR AML-001 trial in acute myeloid leukemia.

This article discusses the current treatment landscape and therapeutic strategies for mantle cell lymphoma, the role of Bruton tyrosine kinase inhibitor therapies in MCL, and insights on new regimens and ongoing clinical trials from leading experts in hematologic malignancies.

The FDA has approved belumosudil for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease following failure of at least 2 prior lines of systemic therapy.

James Foran, MD; Azra Raza, MD; and Gail Roboz, MD, discuss how mutation status in myelodysplastic syndrome may impact treatment considerations.

Daniel Pollyea, MD, MS, discusses the current management of patients with higher-risk myelodysplastic syndrome, the data noted so far with pevonedistat in this paradigm, and other therapies positioned to improve outcomes for this patient population.

Cellular medicine could represent the next frontier in the treatment of patients with cancer and many other diseases with a high unmet need.

David Sallman, MD, discusses the role of hypomethylating agents in the treatment of patients with higher-risk myelodysplastic syndrome, the promise of pevonedistat in this population, the hunt for biomarkers of response to treatment, and remaining areas of unmet need to address with future efforts.

The FDA has lifted a partial clinical hold that was placed on a first-in-human, phase 1b trial evaluating RVU120 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.